Supersize my Pipeline

It was the early 1990s, when biotechs and investors alike were placing big bets on the promise of data from the Human Genome Project. But George Scangos wasn't convinced. At the time, Scangos was working at pharmaceutical behemoth Bayer. He saw many pharmaceutical companies making large deals in genomics, and viewed them as potential mistakes. "I felt like what one got from those collaborations was a whole lot of data," which was only correlative, says Scangos. "What I thought was needed was more of a functional approach."